Navigation Links
Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
Date:8/8/2008

BRIDGEWATER, N.J., Aug. 8 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that U.S. Food and Drug Administration (FDA) has assigned priority review status for its New Drug Application (NDA) for Multaq(R) (dronedarone). The priority review period begins on July 31, 2008.

The priority review is granted to applications in which a new indication or new drug product, if approved, has the potential to present a safe and effective therapy where no satisfactory alternative exists compared to currently available therapies or marketed products.

A registration dossier is also under regulatory review by the European Medicines Agency (EMEA) for a Marketing Authorization Application.

"We are pleased that the FDA has designated Multaq(R) for priority review," said Marc Cluzel, sanofi-aventis Senior Vice President, R&D for sanofi-aventis. "This follows the exciting results of the landmark ATHENA study that showed Multaq(R) significantly decreased the risk of cardiovascular hospitalizations or death from any cause in patients with Atrial Fibrillation."

Atrial fibrillation is a major cause of hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern due to an aging population. Patients suffering from atrial fibrillation have twice the risk of death, an increased risk of stroke and cardiovascular complications, including congestive heart failure. Furthermore atrial fibrillation considerably impairs patients' lives, mainly because of their inability to perform normal daily activities due to complaints of palpitations, chest pain, dyspnoea, fatigue or light-headedness.

About Multaq(R) (dronedarone)

Dronedarone (brand name Multaq(R)) is an investigational new treatment for patients with atrial fibrillation, which has been discovered and developed by sanofi-aventis for t
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
8. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
9. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
10. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  The Alabama Supreme Court, in ... can sue drug makers who mislead doctors into believing that ... The case is Weeks v. Wyeth, and the decision came ... that same case last year. Heninger Garrison Davis attorneys ... patient in the case, Danny Weeks . ...
(Date:8/19/2014)... , Aug. 19, 2014 Minimally Invasive ... medical device company, announced today that Mitsubishi Corporation ... and robotic visualization system in Japan ... sale in Japan in the ... also the exclusive distributor for Karl Storz GMBH & ...
(Date:8/19/2014)... Aug. 19, 2014  As power morcellator lawsuits ... Bernstein Liebhard LLP notes that women in need ... a number of options that do not involve ... According to a report published by The Wall ... options include a mini-laparotomy and vaginal hysterectomy. Non-surgical ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... , Jan. 25 Curemark, LLC , ( www.curemark.com ... neurological diseases, announced that the company is now enrolling patients in Phase ... the country.  The sites are: , Mount Sinai School of Medicine, ... University of Texas, Houston Indiana University, ...
... , MELVILLE, N.Y. , Jan. 25 ... the largest distributor of health care products and services to office-based ... Bradley T. Sheares , Ph.D. to the Company,s Board of Directors. ... a wealth of health care experience to the Henry Schein Board. ...
Cached Medicine Technology:Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 3Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 2Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 3Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 5
(Date:8/20/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief operating officer ... Ore. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... healthcare organization serving a population of more than 35,000 ...
(Date:8/20/2014)... Hope For The Warriors® is excited to announce ... in Washington, DC on Thursday, October 2, 2014 at ... the courage of our wounded service members, their families, ... Got Heart, Give Hope® Celebration will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Inc. ... year on its 33rd annual Inc. 500|5000, an ... The list represents the most comprehensive look at ... entrepreneurs. Companies such as Yelp, Pandora, Timberland, Dell, ... names gained early exposure as members of the ...
(Date:8/20/2014)... Atlanta, GA (PRWEB) August 20, 2014 ... Data to healthcare, Jvion successfully predicted stage iii ... levels that, in some situations, approached 90%. A ... never been achieved in commercial or academic settings. ... and prevent all types of hospital-acquired conditions to ...
(Date:8/20/2014)... Ticketability.com has Theresa Caputo tickets for ... well-known medium has been thrilling many with her amazing ... cities, with tickets becoming available August 15. , Among ... Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, Charlotte, Houston, New ... Diego. The medium’s fans can obtain Theresa Caputo tour ...
Breaking Medicine News(10 mins):Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2
... treatment mainstay for prostate cancer puts men at increased ... large observational study published in the// Sept. 20 Journal ... have high five-year survival rates, but they also have ... study author Nancy Keating, MD, MPH, assistant professor of ...
... Chile announced a tax on airline tickets to raise ... who cannot afford them//. ,Representatives from the five ... Ignacio Lula da Silva of Brazil, were present for ... Annan and former US President Bill Clinton also attended. ...
... are almost twice as likely to attempt suicide as non-Maori ... than other New Zealanders. ,The survey conducted by the ... the prevalence of mental disorders among different ethnic groups in ... including 2600 Maori. ,It was found that thirty percent ...
... Recent studies have revealed that increased levels of ... events// in healthy women according to Boston-based investigators. ... screening of lipoprotein(a) in the population as a ... with cardiovascular risk. Besides that most lipid-correcting therapies ...
... tested as an anticancer agent to treat breast cancer, supports ... ,Duchene muscular dystrophy is a disease characterized by ... According to earlier studies, the functional decline of "dystrophic" ... fiber size. ,The recent study conducted by Dr. ...
... (China): More than 200 children were taken ill after eating ... ,The 223 students were admitted to a hospital and are ... ,Students of Dianshi Town High School began reporting symptoms ... at their school Monday and were immediately hopitalised. ...
Cached Medicine News:Health News:Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease 2Health News:High lipoprotein Levels in women Linked to Cardiovascular Risk 2Health News:Anti-cancer drug may treat muscular dystrophy 2
... The HSV Non-Typing ASR contains primers and ... a 92 bp region of the HSV Type ... requires an instrument that can detect a FAM ... The Cepheid Analyte Specific Reagent* (ASR) program is ...
... compact system is perfect for the office, ... cost effective microhematocrits are required. Featuring a ... offers a range of important benefits: - ... Meets NCCLS standards - Read tubes in ...
... Palomar systems deliver pulsed light over ... multiple power spikes (which may damage skin) ... Cooling technology sends a chilled water supply ... sapphire tip, which is cooled to as ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Medicine Products: